Hikma Pharmaceuticals Plc 20.8% Potential Upside Indicated by Jefferies International

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Jefferies International. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Jefferies International have set a target price of 1960 GBX on its stock. This now indicates the analyst believes there is a possible upside of 20.8% from today’s opening price of 1622 GBX. Over the last 30 and 90 trading days the company share price has decreased 96.5 points and decreased 254.5 points respectively. The 1 year high for the stock price is 2089 GBX while the 52 week low for the share price is 1061.5 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,662.22 GBX and a 200 day moving average of 1,735.35. There are currently 241,467,737 shares in issue with the average daily volume traded being 644,408. Market capitalisation for LON:HIK is £3,898,496,613 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities.

      Search

      Search